This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI). A proteomic study in 2011 determined a direct correlation between NGP mRNA levels and myeloid-derived suppressor cells. Specifically cathepsin B, a catalytic mechanism and potentially biomarker in a variety of cancers and amyloid plaque development, was inhibited by NGP. The significance of NGP as a negative regulator of tumor metastasis makes this antibody ideal for investigators involved in cancer research, as well as Alzheimer’s research.

This affinity purified antibody has been tested for use in IF, and western blot.  Specific conditions for reactivity should be optimized by the end user. Expect a band 39-42 kDa for non reduced and 20-27 kDa for reduced gels corresponding to Ngp by western blotting in the appropriate cell lysate or extract. 

Type: Primary
Antigen: Ngp
Clonality: Polyclonal
Clone:
Conjugation:
Epitope:
Host: Rabbit
Isotype:
Reactivity: rabbit